BRANFORD, CT (May 8, 2017) – Thetis Pharmaceuticals, a pioneer in the development of novel lipid-based drugs for gastrointestinal diseases, today announced pre-clinical data for its lead candidate TP-252. In a study conducted at the Center for Molecular Medicine at UCONN Health Center, TP-252 was shown to produce a reduction in intestinal tumor burden that was equivalent to EPA-FFA in a mouse model of familial adenomatous polyposis (FAP). These data were presented today at Digestive Disease Week in Chicago.
TP-252 (magnesium lys-icosapentate) is a new drug that delivers the free fatty acid of eicosapentaenoic acid (EPA-FFA), a natural agent with demonstrated clinical efficacy in controlling colorectal polyp burden in FAP. Thetis Pharmaceuticals is pursuing TP-252 in FAP, a rare genetic pediatric disease characterized by hundreds to thousands of polyps in the colon that put patients at high risk for colorectal cancer.
“There is a tremendous unmet need for therapies to treat FAP in pediatric patients,” said Gary Mathias, Thetis co-founder and Chief Executive Officer. “While individuals with FAP ultimately require prophylactic colectomy, we believe that TP-252 has the potential to provide a clinically meaningful delay in surgery. That delay can be life changing in young patients for whom the co-morbidities and emotional burden of colectomy are frequently traumatic.”
About Familial Adenomatous Polyposis
Familial adenomatous polyposis (FAP) is a rare genetic disease for which there are no currently approved treatments. FAP is caused by a mutation of the APC gene, a gene that limits the growth of tumors. Nearly 100% of untreated FAP patients will develop colorectal cancer by the age of 60. The current standard of care includes endoscopic surveillance and ultimately, prophylactic colectomy. While a colectomy is effective at reducing the risk of colon cancer, it has major co-morbidities. Therefore, a safe, oral agent to delay surgery is a major unmet medical need for young FAP patients.
About Thetis Pharmaceuticals
Thetis Pharmaceuticals is a biopharmaceutical company pioneering the development of novel lipid-based drugs for gastrointestinal (GI) diseases. Using its proprietary HEALER™ chemistry platform, Thetis creates unique derivatives of bioactive lipids that are clinically or preclinically known to have efficacy in treating GI diseases.
For more information, please visit Thetis Pharmaceuticals’ website at www.thetispharma.com and follow Thetis on Twitter (@thetispharma).
# # #
Jenna R. Conley
Director, Business Development